- Focusing on Patient-outcome performance
- 2 measures of Active and Passive Implants A
- 3 Systematic Review
- 4 Jana Stucke^{¶1*}, Elinor Tzvi-Minker^{¶1}, Andreas Keck^{¶1}
- 5 ¹ Syte Institute, Hamburg, Hamburg, Germany

8 Abstract

6

- 9 Motivation
- 10 Active implantable electronic medical devices are used in different fields of medicine, in
- particular cardiology and neurology. Several papers have been published over the years
- 12 comparing the technical performance of implants between leading manufactures. However, no
- such comparison has been done with respect to "Patient-Reported Outcomes" (PROs) for most
- implant types, despite its importance in evaluating the quality of a medical device. With the
- recent update of the European Union's (EU) regulation on public procurement towards value-
- based medicine, it has become beneficial for manufacturers to focus more on PROs to
- 17 differentiate their products in order to create a marketing leverage. Most importantly,
- investigating PROs can assist shared decision-making, support pharmaceutical labelling claims
- 19 ANT Firthis preprint reparts new separts that has partheen certified by the first and should not be used struide clinical preprints

of PRO comparisons between implant manufacturers across different medical fields and its

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

impact on patients and surgeons. Methods A literature search was conducted for active and passive implant performance comparisons in the area of implantable cardioverter-defibrillator (ICDs), deep brain stimulation (DBS), cochlear implants (CIs) and intraocular lenses (IOLs). The search focused on the availability of manufacturer comparisons with regards to PROs. A total of 640 papers from 2000 until 2022 were screened in detail for the search term "patient reported outcomes" for the different implant types. Next, we analyzed the results by tagging papers based on the specific topics they investigated in their study to enable a cross-comparison. We noted whether the implant manufacturers were mentioned as well as whether a manufacturer comparison was done. Studies were also evaluated based on the number of patients included. Results A total of 38 papers were identified for ICDs, 31 for DBS, 68 for IOLs and 34 for CIs. 50% of the papers for IOL focused on PROs and 22% and 14% for CIs and DBS, whilst mentioning the manufacturers. No papers dealing with PROs could be identified for ICDs. Manufacturer comparison was not attempted by any of the reviewed papers, despite implants such as CIs and DBS having quite a significant impact on the quality of life. **Conclusions** There is an urgent need for clinical studies which focus on PRO comparisons between implants of different manufacturers, to not only provide physicians and patients with critical information that informs their decision prior to implantation, but also to increase the competition between manufacturers, thus, fostering innovation. The former would allow physicians to recommend

- 43 the most suitable implant for the patient. In addition, this will drive manufacturers towards
- 44 PRO focused improvements.

Introduction

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

The use of implantable active and non-active medical devices has increased dramatically in the last few decades. Due to advancements in technology and especially Artificial Intelligence (AI), current state-of-the-art devices can treat conditions that have not been treatable up until now before. These advancements have led the highly competitive medical manufacturing industry to differentiate their products by demonstrating product value beyond the traditional measures of clinical safety and efficacy (Curran, 2018; Squitieri et al., 2017), through patientreported-outcomes (PROs). A PRO is defined as a report of the status of the patient's health condition, by the patient itself or their caregiver or surrogate responder, without prior interpretation (Eton et al., 2014; U.S. Food and Drug Administration, 2009; European Medicines Agency, 2019). It classifies a range of different, patient-related concepts, including personal reports of health status, symptoms, and health-related quality of life (QoL, Calvert et al., 2013). PROs allow for shared decision making between practitioner and patient, which makes them a valuable marketing tool for medical device manufacturers. One sector within the medical device industry, which may profit most from the use of PROs are medical implants. Passive implants have been used since the mid 1950's in the form of breast implants and quickly been followed by active implants, such as pacemakers in 1958. Nowadays numerous passive and active implants from head to toe exist, from dental to hip implants as well as cardiac defibrillators (ICDs) and Cochlear implants (CIs). It is predicted that the global active implantable medical device market will increase its CAGR by 7.7% (Market Data Forecast) by 2026. With personalised medicine gaining more importance due to the rise of AI, medicine in general has become more customer centric. Patient Reported Outcomes (PROs), which assess the impact of a medical treatment or intervention (Rothman

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

et al., 2007), becomes a decision factor for surgeons and patients alike. This is particularly true for implants as they require an intervention and, depending on the implant, most often cannot be easily replaced. For years, studies have been conducted comparing the technical features of different active and passive implant manufacturers in different medical fields (Saad et al., 2002; Semmler et al., 2021; Mens 2007; Plontke et al. 2018; Bon et al, 1997; Nagy et al., 2011). In particular, transcatheter pacemakers and ICDs have been investigated, and the focus of these studies was mainly on lead malfunctions and battery longevity (Ipp, 2021; Hauser et al, 2021, De Meester and Gilles, 2001; Narayanan et al., 2021, Pokorney et al., 2014). However, studies performing outcome-based manufacturer comparisons are rare. This is true for most implant types apart from breast implants, which are commonly used for plastic surgery. Here, a vast number of publications comparing manufacturers can be found (Niechajev et al., 2007; Yoon and Chang, 2020; Henderson et al., 2015). However, active implants may be an intervention with a more drastic impact on a patients' QoL. The implantation of CIs, for example, requires the insertion of an electrode array into the cochlea, whilst deep brain stimulation (DBS) technology requires an accurate placement of the leads in the brain and a personalization of the stimulation parameters according to the severity of the neurological symptoms. Thus, it is of critical importance, especially in these particular areas of active implants to: (1) report systematically on PROs and (2) perform objective manufacturer comparisons that could guide patients and surgeons alike in their decision-making process. In this review, we scanned the literature for studies of both active and passive implants that report patient outcomes. In the area of active implants, we focused on implanted cardiac defibrillators (ICDs), cochlear implants (CIs) and deep brain stimulation (DBS), whereas for passive implants we focused on intraocular lenses (IOLs). The latter was chosen due to its similarity to CIs in affecting sensory perception, and thus PRO. Note that these are exemplary passive and active implants, and there are many more medical implants that could be investigated in future work, such as artificial knees and hips as well as leadless and transvenous pacemakers. The purpose of this review is to demonstrate the availability of manufacturer information in different active and passive implants and to stress the importance of performing comparisons of PROs in the different medical fields.

Methods

Search Strategy

A structured literature search was conducted using both google scholar and PubMed. The search strategy comprised searching for free-text terms "patient reported outcomes", combined with the different implanted devices: "ICD", "Cochlear Implant", "intraocular lenses" and "deep brain stimulation". An initial search found that PubMed showed less relevant hits than Google Scholar and the hits found in the former matched those found on Google Scholar. To this end, two independent reviewers (ETM, JS) scanned the first 150 most relevant (according to Google Scholar relevance algorithm) hits. We selected all papers published after 2000 in peer-reviewed journals. All reviews and commentary articles were discarded.

The literature search was last updated 22nd February 2022. The search targeted published research in scholarly journals, conference proceedings and workshop reports that assesses active or passive implants on a technical or outcome-based basis.

Selection Process

Titles, abstracts, and full articles were subsequently screened by reviewer 1 [JS] applying the inclusion and exclusion criteria (Figure 1). Publications meeting the inclusive criteria, were reviewed a second time by an additional reviewer [ETM]. Figure 1 illustrates the process.




Figure 1Literature Inclusion Flowchart

Data Extraction and analysis

Data was extracted from the included papers in a matrix. The data extraction was mainly done by reviewer 1 [JS] and later re-examined by reviewer 2 [ETM]. The extracted data was

categorised and summarised in a matrix and later exported into tables and graphs. The data matrix is provided for a convenient workflow in Microsoft Excel (version 16.16.5) and can be found in the Appendix.

Results

The following section presents a summary of the extracted data from 171 included studies investigating PROs of active and passive implants for the areas of neurology, cardiology, and otolaryngology. Specifically, we focused on the following devices: implanted cardiac defibrillators (ICDs), cochlear implants (CIs) and deep brain stimulation (DBS), whereas for passive implants we focused on intraocular lenses (IOLs).

Bibliographic Overview

Table 2 shows the number of total publications considered after the reviewing process. Here, we included publications from peer-reviewed journals only. Conference proceedings, workshop publications or case studies were not considered. The Journal of American College for Cardiology (n = 9), Otology & Neurotology (n = 4), Journal of Cataract & Refractive Surgery (n = 22) and Brain (n = 4) represented the journals with most included publications for ICDs, CIs, IOLs and DBS respectively.

Table 1 Bibliographic overview of the included studies

Implant Type	Number of papers before filtering	Number	of	papers	after
		filtering			
ICD	47	38			

DBS	40	31
IOL	89	68
CI	59	34

The included papers were published during the following years for ICDs: 2012 (n = 9), 2015 (n = 4) and 2005 (n = 4); IOLs: 2017 (n = 13), 2021 (n = 12) and 2019 (n = 10); DBS: 2010 (n = 6), 2006 (n = 4) and 2012 (n = 4) and CIs; 2021 (n = 16), 2020 (n = 16) and 2019 (n = 3). This shows that the general interest in PROs is clearly growing for CI and IOLs when compared to DBS and ICDs.

Sample Sizes

The total number of subjects in the included studies varied with implant type with the maximum, minimum and average patient number for each implant being depicted in Table 2. Note, that for ICDs eight studies were retrospective, analysing very large patient databases ranging from 1,820 to 38,912 patients. Large retrospective studies were also performed in the other fields. For DBS, one study had over 5,000 participants, and for CI two studies had more than 1,500 participants. For IOLs, only three studies had over 500 participants. This results in a high average of participants for ICDs. The other implant types had on average between 117 and 237 patients, which can be considered quite high and reflecting the quality of the paper considered in this review. Only DBS and IOL included cohorts of less than 12 subjects which may be due to a specific focus on aetiology.

Table 2 Maximum, Minimum and Average Number of Patients used in the Literature for ICDs, CIs, DBS and IOLs

Implant Type	Maximum Number of	Minimum Number of	Average Number of
	Patients	Patients	Patients
ICD	38,912	12	3,142
CI	2,735	19	180
DBS	5,311	3	237
IOL	710	6	117

Summary of findings in the Literature

162

163

164

- A distribution of the papers according to outcome, as tagged in Table 3, is shown in Figure 2 to Figure
- 166 5. This was done for ease of comparison across implant types. Here, papers were tagged based
- on their overarching topic for ease of cross-comparison in the different medical fields.

168 Table 3 Legend of the taxonomy used for study tagging

Overarching Term	Tagging of papers based on
Safety	Safety of the implant as defined by the authors
QoL	"Quality of Life" directly mentioned in the text or PRO assessed as QoL measure
Complications	Side effects as well as mortality
Psychological	Anxiety, Fear, Depression

Effectiveness	Effectiveness of the implant to treat the patient
Cognitive Improvement	Any type of cognitive ability that improved following implantation
Rehabilitation	Studies focusing on best practices for post-surgery rehabilitation
Performance	Patients' improvement in test scores
Satisfaction	Patient satisfaction with the outcome
PRO	A clear statement of Patient Reported Outcomes in the text
Comparison hearing ability criteria	Only used for CIs. Evaluation of the tests to judge whether an implantation was beneficial

The results show that most papers evaluating PROs for ICDs deal with the psychological effect on the patient, as well as the associated complications of the implantation. We can therefore conclude that these outcomes serve as most significant in this medical field. Several papers (n = 10) also investigated QoL as the main outcome, which is tightly knit to psychological outcomes.




Figure 2 Occurrence of the created taxonomy within the screened ICD studies

For CIs the distribution of topics is less balanced than for ICDs. Here, there is a heavy focus on the patient's performance, in particular speech and hearing perception scores. These scores reflect how well the patient functions with the implant and serve as a comparison to the preoperative state, thus, can be seen as closely related to QoL. PROs and satisfaction played only a minor role in the research.




Figure 3 Occurrence of the created taxonomy within the screened CI studies

Figure 4 shows the distribution of outcomes investigated for IOLs. As for CIs, most studies deal with performance, with satisfaction and QoL lagging much behind. This distribution is very different to the more balanced distribution of outcomes for ICDs.




Figure 4 Occurrence of the created taxonomy within the screened IOL studies

The outcome distribution for DBS is depicted in Figure 5. It can be seen that over 35% of the papers are addressing the effectiveness of DBS to treat different conditions. Performance, which means in this case, how well the patients improved their symptoms in each indication (Parkinson's disease, Dystonia, Essential tremor, Obsessive compulsive disorder and depression) following implantation, and complications are often mentioned alongside effectiveness and are forming the second and third most mentioned topics in the DBS studies reviewed here. Only very few studies evaluated QoL directly, though effectiveness of the therapy is also an indirect indication of QoL.




Figure 5 Occurrence of the created taxonomy within the screened DBS studies

Figure 6 shows a cross-comparison of outcomes for the different implant types. We found that the focus of ICD papers lies heavily on the psychological impact on the patient and complication rate, whereas CI and IOL papers are mainly addressing performance criteria. DBS studies are mostly concerned with the effectiveness of treatment compared to other forms of therapies. Interestingly, there are relatively more papers focusing on QoL for ICDs than for CIs, DBS and IOLs, despite the latter directly impacting perception (visual, hearing, motor). It is also surprising that double the amount of papers on IOLs focus on patient satisfaction than for CIs. Here, a more balanced result would have been expected, in particular, as CI surgery affects hearing perception and similar to IOLs directly affects sensation. The same is true for DBS, which is used for alleviating neurological symptoms in Parkinson's disease and depression. There as well, one would expect more studies investigating patient satisfaction. Generally, as these disorders have a strong effect on quality of life, more papers on the assessment of QoL would have been expected.




Figure 6 Occurrence of the taxonomy across different implant type studies

Additionally, we investigated how many studies dealing with either satisfaction, PRO or QoL, also specifically mention the implant manufacturer. This analysis was done for CIs, IOLs and DBS only, as no such data were available for ICDs. The results are depicted in Figure 7. Only 50% of IOL studies dealing with PROs also mention the implant manufacturer with the number decreasing for CIs and DBS. Here only 22% and 14% of papers also mention the implant manufacturer. Despite the ability to perform cross-manufacturer comparisons of PROs, none of those studies reported such comparisons. Considering that all three implant types significantly influence patients' quality of life this finding is particularly surprising. Clearly, manufacturer comparisons are not straight-forward as they strongly depend on inter-individual parameters which are perhaps difficult to account for. However, we argue that such comparisons can be done when (1) a large number of patients are considered such that interindividual variability is negligible and (2) attempts to match the patients in terms of condition, age, sex and other influencing factors have been made.




Figure 7 Number of papers mentioning the manufacturers and dealing with some form of PRO

Discussion

In this scoping literature review, we found that the majority of papers across implant types were mainly focusing on the performance of the device. The next theme that the studies in this review focused on is QoL assessment. Depending on the implant type, studies focused on different aspects of the implanted devices. Our scoping review also demonstrates that manufacturers of implanted devices were mentioned >95% of the time for DBS and IOLs papers, but only 75% of the time for CIs and <40% of the time for ICDs (see Figure 8).




Figure 8 Percentage of reviewed publications mentioning the manufacturer

However, only 50% of the papers for IOL dealing with PROs and 22% and 14% for CIs and DBS respectively, mentioned the manufacturer in the context of PROs. This is quite surprising as patients, manufacturers and medical professionals alike should be interested in the comparison of implants across manufacturers to be able to make informed decisions when choosing a specific device. This is particularly relevant for implants that directly affect sensory perception, whether or not they stimulate the brain directly. CIs for example, are often implanted in children, thus the specific implant choice can significantly affect patient's quality of life for many years, as well drive cognitive, emotional, and social development (Humphries et. al., 2012; de Almeida et. al., 2015). Importantly we note that none of the papers we present in this scoping review attempted to perform a direct comparison amongst manufacturers with regards to QoL, despite the fact that data are available, sometimes within one centre, to perform such a comparison. As in all reviews, the selection of search terms strongly influences the spectrum of results achieved. It was critical to choose a very specific search term that could apply for all indications, to enable comparisons of outcomes across these different medical areas. Thus, it is possible that different search terms in each indication specifically would have

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

yielded other publications that perform comparisons between manufacturers. However, a heuristic search we performed for CI, using many different search terms, did not yield any papers that present manufacturer comparisons. Patients and medical practitioners alike would greatly benefit from easily accessible data and manufacturer comparisons with regards to PROs to make informed decisions prior implantation. Clearly, these comparisons are highly subjective and vary greatly, depending on the individual tested, their medical history as well as the skills of the surgeon and the rehabilitation process following implantation. Yet, this should not prevent the scientific community from attempting to perform such comparisons for the greater benefit of the medical community, patients and physicians alike. Also manufacturers should be more open to allow those types of comparisons as their product would be able to benefit greatly as it allows for constant improvements. Additionally, with sufficient studies and cohort sizes individual differences would eventually cancel out, thus, enabling informed implant choices and recommendations. Based on the publishing date of the reviewed literature, we may conclude that studies concerning PROs become more relevant especially for CIs, where most of the papers were either published in 2021 or 2020. This testifies for the increased interest of the otolaryngology community in addressing this type of outcome in CI. Similarly, for IOLs, most papers were published in 2017 and 2021, suggesting a similar trend in this field. However, this is not the case for papers on DBS and ICDs. For DBS, most papers are 12 to 16 years old and for ICDs, most papers are 10 to 17 years old. In both fields, the functionality of the sensory system may have a smaller priority in comparison to survival (ICD) and regaining of motor function in movement disorder patients (DBS). The recent advancements in the field of DBS to treat mental health conditions such as Depression and Obsessive Compulsive Disorders (Baldermann et al., 2021; Van Westen et al., 2022; Li et al., 2021; Fenoy et al., 2022; Scangos et al., 2021; Youssef et al., 2021) might drive the field to take a closer look at PROs.

Based on the above, we suggest that future research should focus more on PRO based manufacturer comparisons for active as well as passive implants, to allow patients and surgeons to make informed decisions. Further research should also be conducted on the identification of

Conclusions

appropriate tests to rate patient satisfaction.

In this review, we conducted a literature search on the availability of manufacturer comparisons for outcome-based parameters for active and passive implants. This was done as PROs become more important to patients and surgeons when choosing from a selection of implants by different manufacturers. We found that using the search term 'patient reported outcomes' led to a variety of results, most of them focusing on the performance of the implant, using objective measurement techniques. Within the papers addressing QoL, PROs and patient satisfaction, less than 50% mentioned the implant manufacturer. Therefore, we suggest that there is a gap in published research for active implants and more research must focus on manufacturer comparisons based on PROs. This is particularly important for medical implants in younger patients as in the CI example since the influence on cognitive, social, and emotional processing has a significant impact on their development. This will lead to an informed decision-making process by patients and surgeons to guarantee the best long-term outcomes. It also fosters innovation as manufacturers are forced to continuously improve their products.

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

Acknowledgments The authors state no conflict of interest. Syte receives financial compensation for consultation to Cochlear, MedEl and Abbott in the past. References De Almeida RP, Matas CG, Vieira Couto MI, de Carvalho ACM. Quality of life evaluation in children with cochlear implants. CoDAS. 2015; 27 (1). Baldermann JC, Schüller T, Kohl S, Voon V, Li N, Hollunder B, Figee M, Haber SN, Sheth SA, Mosley PE, Huys D, Johnson KA, Butson C, Ackermans L, van der Vlis TB, Leentjens AFG, Barbe M, Visser-Vandewalle V, Kuhn J, Horn A. Connectomic Deep Brain Stimulation for Obsessive-Compulsive Disorder. Biological Psychiatry. 2021; 90 (10): 678-688. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. CONSORT PRO Group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013; 309(8): 814-822. Curran J. Medical Device Manufacturing in the US (Industry Report 33451b). Retrieved August 2, 2018, from IBISWorld database. De Meester A, Gilles PH. ICD Malfunction Caused by Excessive Defibrillation Charge Time. Pacing and Clinical Electrophysiology. 2001; 24: 518-519. https://doi.org/10.1046/j.1460-9592.2001.00518.x

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

Eton DT, Beebe TJ, Hagen PT et al.. Harmonizing and consolidating the measurement of patient-reported information at health care institutions: a position statement of the Mayo Clinic. Patient Relat Outcome Meas. 2014; 5:7e15. European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man - the use of patient-reported outcome (PRO) measures in oncology studies. 2016; Available from: https://www.ema.europa.eu/en/appendix-2- guidelineevaluation-anticancer-medicinal-products-man-use-patient-reported-outcome-pro. Accessed: 25.02.2022. Fenoy AJ, Quevedo J, Soares JC. Deep brain stimulation of the "medial forebrain bundle": a strategy to modulate the reward system and manage treatment-resistant depression. Mol Psychiatry. 2022; (27): 574–592. Bon GG, Von Mensdorff-Pouilly S, Kenemans P, van Kamp G J, Verstraeten RA, Hilgers J, Meijer S, Vermorken JB. Clinical and technical evaluation of ACS™BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays, Clinical Chemistry. 1997; 43 (4): 585-593. Hauser RG, Casey SA, Gitter CB. et al.. Reliability and longevity of implantable defibrillators. J Interv Card Electrophysiol. 2021; 62: 507–518. Henderson PW, Nash D, Laskowski M. et al.. Objective Comparison of Commercially Available Breast Implant Devices. Aesth Plast Surg. 2015; 39: 724–732. Hölbl M, Kompara M, Kamišalić A, Nemec Zlatolas LJS. A Systematic Review of the Use of Blockchain in Healthcare. 2018; 10 (10): 470.

347 Humphries T, Kushalnagar P, Mathur G, Napoli DJ, Padden C, Rathmann C, Smith SR. 348 Language acquisition for deaf children: Reducing the harms of zero tolerance to the use of 349 alternative approaches. Harm Reduction Journal. 2012; 16 (9). 350 Ip J.E. Premature battery depletion of EMBLEM subcutaneous implantable cardioverter-351 defibrillators. J Cardiovasc Electrophysiol. 2021; 32: 565–567. Li N, Hollunder B, Baldermann JC, Kibleur A. Treu S, Akram H, Al-Fatly B, Strange BA, 352 353 Barcia JA, Zrinzo L, Joyce EM, Chabardes S, Visser-Vandewalle V, Polosan M, Kuhn J, Kühn, 354 AA, Horn A. A Unified Functional Network Target for Deep Brain Stimulation in Obsessive-355 Compulsive Disorder. Biological Psychiatry. 2021; 90 (10): 701-713. 356 Market Data Forecast. Global Active Implantable Medical Devices Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product & Region - Industry 357 Online: 358 **Forecast** (2021)to 2026). 2021; Available 359 https://www.marketdataforecast.com/market-reports/active-implantable-medical-devices-360 market. Accessed: 23.02.2022. 361 362 Mens, LHM. Advances in Cochlear Implant Telemetry: Evoked Neural Responses, Electrical 363 Field Imaging, and Technical Integrity. Trends in Amplification. 2007; 11(3):143-159. 364 Nagy ZZ, Kranitz K, Takacs AI, Kovacs I, Knorz M C. Comparison of Intraocular Lens 365 Decentration Parameters After Femtosecond and Manual Capsulotomies. Journal of 366 367 Refractive Surgery. 2011; 27 (8).

- Narayanan CA, Katcher B, Coleman S, Butts L, Homoud MK, Garlitski AC, Weinstock J, 369 370 Link, MS, Madidas C. Accelerated Battery Depletion in Subcutaneous Implantable 371 Cardioverter-Defibrillators. JACC: Clinical EP. 2021; 7 (6) 806–808. 372 Niechajev I, Jurell G, Lohjelm L. Prospective Study Comparing Two Brands of Cohesive Gel 373 374 Breast Implants with Anatomic Shape: 5-Year Follow-Up Evaluation. Aesthetic Plastic 375 Surgery. 2007; 31. 697 – 710. 376 377 Plontke SK, Kösling S, Rahne T. Cochlear Implantation After Partial or Subtotal 378 Cochleoectomy for Intracochlear Schwannoma Removal-A Technical Report. Otol Neurotol. 379 2018; 39 (3): 365-371. 380 381 Pokorney SD, Greenfield RA, Atwater BD, Daubert JP, Piccini JP. Novel mechanism of 382 premature battery failure due to lithium cluster formation in implantable cardioverter-383 defibrillators. Heart Rhythm. 2014; 11 (12): 2190-2195. 384 Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B. Patient-Reported 385 386 Outcomes: Conceptual Issues, Value in Health, 2007, 10 (2): \$66-\$75, 387 388 Saad EB, Saliba WI, Schweikert RA, Al-Khadra AS, Abdul- Karim A, Niebauer M J, Wilkoff
- 390 Results and Comparison with Extraction of Pacemaker Leads. Pacing and Clinical

BL. Nonthoracotomy Implantable Defibrillator Lead Extraction:

391 Electrophysiology. 2003.

389

- 393 Scangos, KW, Makhoul GS, Sugrue LP et al. State-dependent responses to intracranial brain
- 394 stimulation in a patient with depression. Nature Medicine. 2021; 27: 229–231.
- 396 Semmler G, Barbieri F, Thudt K, Vock P, Mörtl D, Mayr H, Wollmann CG, Adukauskaite A,
- 397 Pfeifer B, Senoner T, Dichtl W. Long-Term Technical Performance of the Osypka QT-
- 398 5® Ventricular Pacemaker Lead. J. Clin. Med. 2021; 10: 639.
- 400 Squitieri L, Bozic KJ, Pusic AL. The role of patient-reported outcome measures in value-based
- 401 payment reform. Value Health. 2017; 20 (6): 834–836.
- 402 U.S. Food and Drug Administration. Patient-Reported Outcome Measures: Use in Medical
- 403 Product Development to Support Labeling Claims. 2009; Available from:
- 404 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-
- 405 reported-outcome-measures-use-medical-product- development-support-labeling-claims.
- 406 Accessed: 23.02.2022.

- Van Westen M, Rietveld E, Bergfeld IO, de Koning P, Vullink N, Ooms P, Graat I, Liebrand
- 408 L, van den Munckhof P, Schuurman R, Denys D. Optimizing Deep Brain Stimulation
- 409 Parameters in Obsessive-Compulsive Disorder. Neuromodulation: Technology at the Neural
- 410 Interface. 2021; 24 (2): 307-315.
- 411 Youssef NA, Phung P, Patel RS. Characteristics of patients who received deep brain
- 412 stimulation in obsessive-compulsive disorder versus major depressive disorder. Journal of
- 413 Psychiatric Research. 2021; 136: 384-387.
- 414 Yoon S, Chang JH. Short-term Safety of a Silicone Gel-filled Breast Implant: A Manufacturer-
- 415 sponsored, Retrospective Study. Plastic Reconstruction Surgery Global Open. 2020; 8 (5).